{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:59:57Z","timestamp":1781153997912,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the only curative option for certain malignant hematopoietic disorders, yet its benefits are limited by the development of graft-versus-host disease (GVHD). Chronic GVHD (cGVHD) is often characterized by chronic inflammation and fibrosis, propagated by alloreactive donor B- and T-cell involvement. Bruton tyrosine kinase (BTK) is the downstream effector in the B-cell receptor signaling pathway and further has a crucial role in mast cell activation, both of which are critical in the pathogenesis of cGVHD. Selective inhibition of BTK may be beneficial in ameliorating cGVHD pathogenesis. In this study, we evaluated the efficiency of acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, using a murine sclerodermatous cGVHD model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Recipient BALB\/c mice received total body irradiation (800cGy), followed by infusion of bone marrow and splenocytes of either syngeneic (BALB\/c) or allogeneic (B10.D2) mice, and were subsequently treated with acalabrutinib or control starting three weeks after HSCT until the end of week 8. Mice were monitored for clinical signs of GVHD, survival, organ pathology of skin and other organs, and inflammatory mediator expression in serum and skin. RNA sequencing and immunohistochemistry were performed in skin to understand the pharmacological mechanisms of BTK inhibition in sclerodermatous cGVHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Acalabrutinib treatment showed better survival, improved clinical cGVHD scores, and reduced skin pathology. Significant reductions in dermal thickness and skin fibrosis, and mast cell numbers in the acalabrutinib-treated group.\n                      <jats:italic>In vitro<\/jats:italic>\n                      , experiments on mast cell activation show that increased pro-inflammatory chemokines CCL2, CCL3, and CCL4 were effectively inhibited by acalabrutinib in a dose-dependent manner. Chemokine analysis from serum samples revealed significant differences in CXCL10, CXCL13, and CCL22 levels compared to the allogeneic control group. Furthermore, the acalabrutinib treatment showed decreased B220\n                      <jats:sup>+<\/jats:sup>\n                      cells and CD3 infiltration in the skin. RNA-seq analysis of skin identified genes associated with keratinization that were downregulated with acalabrutinib treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results demonstrate that specific inhibition of BTK with acalabrutinib has a potentially beneficial role in ameliorating sclerodermatous cGVHD by improving the survival and clinical benefits and warrants further investigation in patients with cGVHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1843217","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:38:18Z","timestamp":1781152698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Vasantharaja","family":"Raguraman","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Mysinger","sequence":"additional","affiliation":[{"name":"Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University","place":["Huntington, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanid","family":"Mohiyuddin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwan","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kesler","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University","place":["Huntington, WV, United States"]},{"name":"Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilnathan","family":"Palaniyandi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri","place":["Columbia, MO, United States"]},{"name":"Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri","place":["Columbia, MO, United States"]},{"name":"Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: Current status and future directions","volume":"11","author":"Saidu","year":"2020","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/biomedicines5040061","article-title":"The role of B cell targeting in chronic graft-versus-host disease","volume":"5","author":"Rhoades","year":"2017","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: Biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1182\/BLOOD-2017-11-784017","article-title":"B-cell targeting in chronic graft-versus-host disease","volume":"131","author":"Zeiser","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1158\/1538-7445.AM2015-2596","article-title":"Abstract 2596: ACP-196: a novel covalent Bruton\u2019s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients","volume":"75","author":"Covey","year":"2015","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V126.23.2908.2908","article-title":"ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity","volume":"126","author":"Harrington","year":"2015","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/S13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02470","article-title":"Mast cells are mediators of fibrosis and effector cell recruitment in dermal chronic graft-vs.-host disease","volume":"10","author":"Strattan","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V88.8.3230.BLOODJOURNAL8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of\u00a0BTK\u00a0and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1182\/BLOOD-2016-04-709543","article-title":"CXCL10: most consistent cGVHD biomarker","volume":"127","author":"Paczesny","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/S10753-017-0609-2","article-title":"B lymphocyte chemoattractant (CXCL13) is an indicator of acute gastrointestinal GVHD in murine model","volume":"40","author":"Cao","year":"2017","journal-title":"Inflammation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40246-021-00374-9","article-title":"Update\u00a0of\u00a0the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders","volume":"16","author":"Ho","year":"2022","journal-title":"Hum Genomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24065603","article-title":"A kaleidoscope of keratin gene expression and the mosaic of its regulatory mechanisms","volume":"24","author":"Kalabusheva","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00963","article-title":"Unraveling the mechanisms of cutaneous graft-versus-host disease","volume":"9","author":"Santos e Sousa","year":"2018","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/S41409-023-02001-8","article-title":"Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease","volume":"58","author":"Palaniyandi","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"Soci\u00e9","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/JBC.273.18.10979","article-title":"Bruton\u2019s tyrosine kinase-mediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal kinase activation pathway","volume":"273","author":"Hata","year":"1998","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00229","article-title":"Cytokinergic IgE action in mast cell activation","volume":"3","author":"Bax","year":"2012","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4049\/JIMMUNOL.1200677","article-title":"Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic GVHD","volume":"189","author":"Young","year":"2012","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0016582","article-title":"Expression profiling of major histocompatibility and natural killer complex genes reveals candidates for controlling risk of graft versus host disease","volume":"6","author":"Novota","year":"2011","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63776-5","article-title":"Kinetics of gene expression in murine cutaneous graft-versus-host disease","volume":"164","author":"Sugerman","year":"2004","journal-title":"Am J Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/J.1524-475X.2011.00709.X","article-title":"The role of the epidermis and the mechanism of action of occlusive dressings in scarring","volume":"19","author":"Mustoe","year":"2011","journal-title":"Wound Repair Regener"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/PATH.1737","article-title":"Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars","volume":"206","author":"Bellemare","year":"2005","journal-title":"J Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/JIDSYMP.2011.1","article-title":"The role of chronic inflammation in cutaneous fibrosis: Fibroblast growth factor receptor deficiency in keratinocytes as an example","volume":"15","author":"Meyer","year":"2011","journal-title":"J Invest Dermatol Sympos Proc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/JID.2010.120","article-title":"Epithelial cells promote fibroblast activation via IL-1\u03b1 in systemic sclerosis","volume":"130","author":"Aden","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/JID.2014.253","article-title":"Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9","volume":"134","author":"Nikitorowicz-Buniak","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/J.XJIDI.2025.100373","article-title":"Insights into keratinocyte and immunologic landscape in cutaneous graft-versus-host disease through single-cell transcriptomics","volume":"5","author":"Petty","year":"2025","journal-title":"JID Innov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1843217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:38:23Z","timestamp":1781152703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1843217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1843217"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1843217","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1843217"}}